Skip to content

Bioavailability of orally administered gamma-glutamylcysteine

Bioavailability study to determine whether a single oral dose of gamma-glutamylcysteine (GGC) sodium salt can transiently increase glutathione content of the white blood cells and brain tissue of healthy volunteers.

Status
Suspended
Phases
Phase 1
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12612000952842
Enrollment
18
Registered
2012-09-05
Start date
2013-03-25
Completion date
2016-06-15
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Gamma glutamylcysteine (GGC) is commonly found in many foods, such as garlic and whey, which are anecdotally associated with numerous health benefits. GGC can potentially be used by the body to synthesise the commonly termed “master antioxidant” glutathione, which is responsible for protecting our cells from oxidative stress and for the elimination of toxins. As we age our body’s capacity to produce sufficient glutathione progressively declines leaving us vulnerable to many age related diseases and disorders. In this study, we will investigate whether oral administered GGC can be of benefit in increasing the glutathione content in blood cells in young. mature and aged populations.

Interventions

On separate days with a one week washout, participants will receive double blinded single oral doses of gamma-glutamylcysteine (GGC) in the range of 250 mg to 4g (placebo control glucose) . Participants will range from 18 to 20 years, with the only exclusions being smokers, pregnancy, and metal medical implants (MRI). Glutathione levels will be monitored periodically for up to 7 hours following administration by the taking of blood samples (lymphocyte glutathione content) and/or by MRI/MRS (br

On separate days with a one week washout, participants will receive double blinded single oral doses of gamma-glutamylcysteine (GGC) in the range of 250 mg to 4g (placebo control glucose) . Participants will range from 18 to 20 years, with the only exclusions being smokers, pregnancy, and metal medical implants (MRI). Glutathione levels will be monitored periodically for up to 7 hours following administration by the taking of blood samples (lymphocyte glutathione content) and/or by MRI/MRS (brain tissue content).

Sponsors

University of New South Wales
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

Aged 20 - 80 years, reasonable health, non-smoker, non alcoholic, not pregnant, and not surgically fitted with metal medical devices (e.g. pace makers, Cochlear implants) . Healthy body weight [body mass index (BMI) 18.5 - 25 kg/m2]

Exclusion criteria

smokers, alcoholics, any illnesses requiring regular medication

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 11, 2026